

Material Safety Data Sheet

Version 4.0
Revision Date 02/27/2010
Print Date 03/20/2011

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Todralazine hydrochloride

Product Number : T9765

Brand : Fluka

Company : Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone : +18003255832

Fax : +18003255052

Emergency Phone # : (314) 776-6555

2. HAZARDS IDENTIFICATION

Emergency Overview

OSHA Hazards

Target Organ Effect, Harmful by ingestion.

Target Organs

Cardiovascular system.

GHS Label elements, including precautionary statements

Pictogram



Signal word

Warning

Hazard statement(s)

H302 + H312

Harmful if swallowed or in contact with skin.

H332

Harmful if inhaled.

Precautionary statement(s)

P261

Avoid breathing dust/fume/gas/mist/vapours/spray.

P264

Wash skin thoroughly after handling.

P270

Do not eat, drink or smoke when using this product.

P271

Use only outdoors or in a well-ventilated area.

P280

Wear protective gloves/protective clothing.

P301 + P312

IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.

P302 + P352

IF ON SKIN: Wash with plenty of soap and water.

P304 + P340

IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.

P312

Call a POISON CENTER or doctor/physician if you feel unwell.

P322

Specific measures (see supplemental first aid instructions on this label).

P330

Rinse mouth.

P363

Wash contaminated clothing before reuse.

P501

Dispose of contents/container to an approved waste disposal plant.

HMIS Classification

Health hazard:

1

Chronic Health Hazard:

*

Flammability:

0

Physical hazards:

0

NFPA Rating
Health hazard: 1
Fire: 0
Reactivity Hazard: 0

Potential Health Effects

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Ingestion Harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms : Ecarazine
Formula : $C_{11}H_{12}N_4O_2 \cdot HCl$
Molecular Weight : 268.7 g/mol

CAS-No.	EC-No.	Index-No.	Concentration
Todralazine hydrochloride			
3778-76-5	-	-	-

4. FIRST AID MEASURES

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance.

If inhaled

If breathed in, move person into fresh air. If not breathing give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire-fighters

Wear self contained breathing apparatus for fire fighting if necessary.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions

Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation.

Environmental precautions

Do not let product enter drains.

Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.

7. HANDLING AND STORAGE

Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Conditions for safe storage

Keep container tightly closed in a dry and well-ventilated place.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment**Respiratory protection**

Where risk assessment shows air-purifying respirators are appropriate use a dust mask type N95 (US) or type P1 (EN 143) respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection

Handle with gloves. For prolonged or repeated contact use protective gloves.

Eye protection

Safety glasses with side-shields conforming to EN166

Skin and body protection

Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Hygiene measures

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

9. PHYSICAL AND CHEMICAL PROPERTIES**Appearance**

Form	solid
------	-------

Safety data

pH	no data available
Melting point	no data available
Boiling point	no data available
Flash point	no data available
Ignition temperature	no data available
Lower explosion limit	no data available
Upper explosion limit	no data available
Water solubility	no data available

10. STABILITY AND REACTIVITY**Chemical stability**

Stable under recommended storage conditions.

Conditions to avoid

no data available

Materials to avoid

no data available

Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NO_x), Hydrogen chloride gas

11. TOXICOLOGICAL INFORMATION**Acute toxicity**

LD50 Oral - rat - 598 mg/kg

Remarks: Lungs, Thorax, or Respiration:Dyspnea. Lungs, Thorax, or Respiration:Other changes. Blood: Hemorrhage.

Skin corrosion/irritation

no data available

Serious eye damage/eye irritation

no data available

Respiratory or skin sensitization

no data available

Germ cell mutagenicity

no data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

Developmental Toxicity - mouse - Oral

Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Specific Developmental Abnormalities: Musculoskeletal system.

Developmental Toxicity - mouse - Oral

Effects on Embryo or Fetus: Fetal death.

Specific target organ toxicity - single exposure (GHS)

no data available

Specific target organ toxicity - repeated exposure (GHS)

no data available

Aspiration hazard

no data available

Potential health effects

Inhalation	May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion	Harmful if swallowed.
Skin	May be harmful if absorbed through skin. May cause skin irritation.
Eyes	May cause eye irritation.

Signs and Symptoms of Exposure

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Additional Information

RTECS: FE2778600

12. ECOLOGICAL INFORMATION

Toxicity

no data available

Persistence and degradability

no data available

Bioaccumulative potential

no data available

Mobility in soil

no data available

PBT and vPvB assessment

no data available

Other adverse effects

no data available

13. DISPOSAL CONSIDERATIONS**Product**

Observe all federal, state, and local environmental regulations.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION**DOT (US)**

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION**OSHA Hazards**

Target Organ Effect, Harmful by ingestion.

DSL Status

This product contains the following components that are not on the Canadian DSL nor NDSL lists.

Todalazine hydrochloride

CAS-No.
3778-76-5

SARA 302 Components

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard, Chronic Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Todalazine hydrochloride

CAS-No.
3778-76-5

Revision Date

New Jersey Right To Know Components

Todalazine hydrochloride

CAS-No.
3778-76-5

Revision Date

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION**Further information**

Copyright 2010 Sigma-Aldrich Co. License granted to make unlimited paper copies for internal use only.

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Co., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.
